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The 2008 World Health Organization (WHO) criteria were used
to identify 88 consecutive Mayo Clinic patients with ‘myelodys-
plastic syndrome with isolated del(5q)’ (median age 74 years;
60 females). In all, 60 (68%) patients were followed up to the
time of their death. Overall median survival was 66 months;
leukemic transformation was documented in ﬁve (5.7%) cases.
Multivariable analysis identiﬁed age X70 years (P¼0.01),
transfusion need at diagnosis (P¼0.04) and dysgranulopoiesis
(P¼0.02) as independent predictors of shortened survival; the
presence of zero (low risk), one (intermediate risk) or X2 (high
risk) risk factors corresponded to median survivals of 102, 52
and 27 months, respectively. Janus kinase 2 (JAK2), thrombo-
poietin receptor (MPL), isocitrate dehydrogenase 1 (IDH1) and
IDH2 mutational analysis was performed on archived bone
marrows in 78 patients; JAK2V617F and MPLW515L mutations
were shown in ﬁve (6.4%) and three (3.8%) patients, respec-
tively, and did not seem to affect phenotype or prognosis. IDH
mutations were not detected. Survival was not affected by
serum ferritin and there were no instances of death directly
related to iron overload. The current study is unique in its strict
adherence to WHO criteria for selecting study patients and
providing information on long-term survival, practical prognos-
tic factors, baseline risk of leukemic transformation and the
prevalence of JAK2, MPL and IDH mutations.
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published online 20 May 2010
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Introduction
‘Myelodysplastic syndrome with isolated del(5q)’ constitutes
one of seven World Health Organization (WHO)-deﬁned
categories of adult myelodysplastic syndromes (MDS).
1 It is to
be recalled that the traditional deﬁnition of ‘the 5q  syndrome’
stipulated a phenotype characterized by macrocytic anemia,
erythroid hypoplasia, normal or elevated platelet count,
hypolobulated megakaryocytes and isolated del(5q).
2 However,
not all cases of del(5q)-associated MDS variants ﬁt neatly into
this original description and can be histologically and cyto-
genetically diverse. For example, in a recent report of 130 MDS
patients who had del(5q) as part of their karyotype, only 6 (5%)
met the classical description of the ‘5q  syndrome’.
3 The
current WHO deﬁnition for ‘MDS with isolated del(5q)’ has
clariﬁed the diagnostic criteria and does not specify mega-
karyocyte morphology, extent of trilineage dysplasia or ring
sideroblast count, but requires the presence of an isolated
del(5q), a blast count of o5% in the bone marrow (BM) and
o1% in the peripheral blood (PB) and absence of Auer rods.
1
Very few published studies on ‘5q  syndrome’ or del(5q)-
associated MDS follow standard criteria for patient selection;
it is, therefore, not surprising that the reported median survival
ﬁgures range from 28 months to 12 years and leukemic transfor-
mation rates from 7 to 16%.
3–8 Isolated del(5q) abnormality
can occur in both acute and chronic myeloid malignancies
including myeloproliferative neoplasms (MPNs).
9,10 Further-
more, among MDS patients with del(5q), most do not meet
the WHO criteria for classiﬁcation under the category of ‘MDS
with isolated del(5q)’. For example, in the aforementioned study
of 130 patients with del(5q)-associated MDS, 32 (25%) patients
had therapy-related MDS, 52 (40%) had refractory anemia with
excess blast, 19 (15%) had unclassiﬁable myelodysplastic
syndrome and the majority had additional cytogenetic abnorm-
alities.
3 Similarly, the number of patients that are potentially
classiﬁable as ‘MDS with isolated del(5q)’ in other studies
constitutes only a fraction of their study population and the
sample size for informative patients rarely exceeds 50 patients.
Therefore, it has been difﬁcult to discern the true natural history
of patients with ‘MDS with isolated del(5q)’ and an accurate
account of their molecular phenotype. It is with this background
that we report on mature survival data and information on Janus
kinase 2 (JAK2), thrombopoietin receptor (MPL) and isocitrate
dehydrogenase (IDH) mutational frequencies among 88 con-
secutive patients who clearly met the 2008 WHO diagnostic
criteria for ‘MDS with isolated del(5q)’.
Materials and methods
After obtaining approval by the Mayo Clinic institutional review
board, we queried an institutional cytogenetic database from
1989 to 2009, in order to identify patients whose BM karyotype
analysis revealed at least two metaphases with isolated deletions
of chromosome 5q. Medical records, BM and cytogenetic
specimens were reviewed in all cases to ensure accuracy of
diagnosis. Only those patients who met the 2008 WHO criteria
for ‘MDS with isolated del(5q)’ were included in the data
analysis.
1 In patients who were alive, every attempt was made to
update follow-up information, by means of a questionnaire/
telephone call sent to both patients and their primary doctors,
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Morphology
Morphological evaluation of the BM and PB was performed
according to the standard evaluation protocol at the Mayo
Clinic. All 88 cases in the current study had their BM
examination and cytogenetic studies performed and the
diagnosis was reported at our institution. In addition, BM and
PB slides were available for re-review in 80 patients. Dysplasia
was recorded only if the dysplastic features within one cell line
constituted more than 10% of the cell line examined.
Dyserythropoiesis was deﬁned by the presence of nuclear–
cytoplasmic asynchrony, multinuclearity, nuclear fragmenta-
tion, internuclear bridging or irregular nuclear outlines.
Dysgranulopoiesis was deﬁned by the presence of nuclear
hypolobation (for example, pseudo-Pleger–Huet anomaly),
cytoplasmic hypogranulation, atypical nuclear segmentation or
signiﬁcant dual butyrate and chloroacetate esterase-positive
myeloid precursor cells. Megakaryocytic dysplasia was deﬁned
by the presence of micromegakaryocytes and megakaryocytes
with nonlobated and hypolobated nuclei.
Cytogenetics and molecular studies
Cytogenetic studies were performed using short-term BM
cultures along with conventional G- or Q-banding ﬂuores-
cence.
11 When possible, a total of 20 metaphases were
evaluated. The ﬁndings were described according to the
International Society of Cytogenetic Nomenclature.
12 Archived
BM cell pellets were stored at  701C in methanol:glacial acetic
acid (2:1) ﬁxative. After appropriate washing techniques, the
DNA on these patients was extracted by using the Qiagen DNA
Mini extraction kit (Qiagen, Santa Clarita, CA, USA) and
analyzed for JAK2V617F and MPL (exon 10) mutations, by
using previously described methods.
13,14
IDH1 and IDH2 mutation analysis was performed by direct
nucleotide sequencing. The primer sequences used to amplify
IDH1 exon 4 were: 50-CGGTCTTCAGAGAAGCCATT-30 (sense)
and 50-CACATTATTGCCAACATGAC-30 (anti-sense), as pre-
viously described.
15 IDH2 was ampliﬁed using 50-CCACTATTA
TCTCTGTCCTC-30 (sense) and 50-GCTAGGCGAGGAGCTCCA
GT-30 (anti-sense) primers, as previously described.
16 Brieﬂy,
both reactions were performed in 25ml volume, containing 100ng
of DNA, 0.25U Taq polymerase, 0.3mM each of dATP, dCTP,
dGTP and dTTP, 5mlo fa1 0   PCR buffer (Roche Diagnostics,
Indianapolis, IN, USA) and 0.2mM each of sense and anti-sense
primers. The reaction was denatured at 941C for 3min followed
by 35 cycles of denaturing at 941C for 30s, annealing at 571Cf o r
30s and extension at 721C for 40s. After a ﬁnal extension at 721C
for 2min, the products were conﬁrmed by running on 1.3%
agarose gel and puriﬁed using Qiagen PCR Quick Puriﬁcation Kit
(Qiagen). The product was submitted to automated sequencing by
ABI PRISM 3730xl analyzer (Applied Biosystems Inc, Foster City,
CA, USA) to screen for the presence of mutations.
Statistical analysis
Descriptive and statistically analyzed data were based on
parameters collected at the time of initial diagnosis. Statistical
procedures used were conventional and all data were analyzed
by using StatView (SAS Institute, Cary, NC, USA). All P-values
were two-tailed and statistical signiﬁcance was set at the level of
Po0.05. Continuous variables were summarized as medians
and ranges. Categorical variables were described as count and
relative frequency. Comparison between categorical variables
was performed by w
2-statistics. Comparison of continuous
variables between categories was performed by either Mann–
Whitney U-test or Kruskal–Wallis test. Survival analysis was
performed by the Kaplan–Meier method taking the interval from
the date of diagnosis to death or last contact. The log-rank test
was used to compare survival data. Cox regression model was
used for multivariable analysis.
Results
Clinical, histological and cytogenetic details at
presentation
Over 24000 unique patient cytogenetic studies performed at
our institution, mainly between 1989 and 2009, were screened
and 190 (B1%) patients with isolated del(5q) were identiﬁed.
Table 1 lists the spectrum of hematological disorders associated
with an isolated del(5q) abnormality, and also provides
information on their JAK2V617F mutational status and subse-
quent disease transformation into acute myeloid leukemia
(AML) or a more aggressive disease phenotype. Among these
190 patients with isolated del(5q), 88 (B46%) met the 2008
WHO criteria for ‘MDS with isolated del(5q)’. The median age
for this cohort was 74 years (range, 28–89; 60 females) and
61 (69%) patients were transfusion dependent at the time of
diagnosis. The main clinical and laboratory features of these 88
patients, stratiﬁed by the presence or absence of the JAK2V617F
mutation, are outlined in Table 2. Cytogenetic data were
available for re-review in all 88 cases, and BM and PB
specimens were available for re-review in 80 patients; Table 3
describes their pathological and cytogenetic details.
Molecular studies
Archived BM was available for JAK2, MPL and IDH mutation
analysis in 78 patients; 5 (6.4%) patients harbored the
JAK2V617F mutation (JAK2V617F allele burden ranged from
1 to 10%) and 3 (B4%) patients harbored the MPLW515L
mutation. One patient carried both mutations. Neither IDH1
nor IDH2 mutations were detected in any patient. As illustrated
in Table 2, there were no signiﬁcant differences between
JAK2V617F-positive and -negative cases in terms of age,
hemoglobin level, leukocyte count, platelet count or clinical
outcome. Ring sideroblasts were not seen in four of the ﬁve
JAK2-mutated cases. Table 4 provides clinical and BM
morphology details of the three patients with MPL mutations;
none of these three patients displayed thrombocytosis and their
survival did not seem to be compromised by the presence of the
mutation (Table 4).
Comorbid conditions and treatment
Eight patients had coexisting hematological disorders including
two with chronic lymphocytic leukemia, two monoclonal
gammopathy of undetermined signiﬁcance, two multiple
myeloma and one paroxysmal nocturnal hemoglobinuria. In
total, 47 (53%) patients were prescribed drug therapy in an
attempt to ameliorate anemia: erythropoiesis-stimulating agents
in 28 (32%) patients, lenalidomide in 18 (20%) and thalidomide,
azacytidine and danazol in one patient each. Of the 18 patients
who received lenalidomide therapy, 5 (28%) achieved transfu-
sion independence, 5 (28%) had a decrease in their transfusion
requirement and 8 (44%) showed no response. None of the ﬁve
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mide therapy and two had received erythropoiesis-stimulating
agents therapy. The cause of death was documented in 29 (48%)
of the 60 patients who had died: 8 pneumonia, 7 cardiac failure,
4 cardiac arrest, 3 sepsis, 2 metastatic lung cancer and 1 each
of metastatic breast cancer, myocardial infarction, stroke and
lower gastrointestinal bleed. None of the deaths were directly
related to iron overload.
Survival, leukemic transformation rates and
prognostic variables
Median follow-up for the entire study population, including
deceased patients, was 33 months (range, 0–158). During this
period 60 (68%) patients had died and 7 had documented
disease transformation, that is, 5 (5.7%) AML and one case each
of refractory anemia with excess blast-1 and chronic myelomo-
nocytic leukemia. The median time interval between diagnosis
Table 2 Clinical and laboratory features of 88 patients with the World Health Organization (WHO)-deﬁned ‘myelodysplastic syndrome with
isolated del(5q)’, stratiﬁed by the presence or absence of the JAK2V617F mutation
Variable Entire cohort
(n¼88)
JAK2V617F
negative (n¼78)
JAK2V617F
positive (n¼5)
JAK2V617F
unknown (n¼5)
P
a-value
Age in years (median and range) 74 (28–89) 74 (28–89) 74 (70–80) 79 (70–81) 0.54
Sex, M/F 28/60 23/55 3/2 2/3 0.15
Hemoglobin in g per 100ml
(median and range)
9.2 (4.7–13.3) 9.3 (4.7–13.3) 9.1 (5.4–10.6) 9.0 (8.2–9.2) 0.32
MCV in ﬂ (median and range) 103 (79–130) 102 (79–130) 102 (92–116) 104 (98–111) 0.45
Leukocyte count  10
9 cells per l
(median and range)
4.7 (1.5–27.3) 4.7 (1.5–27.3) 4.5 (3.5–10.7) 5.1 (3–7.8) 0.98
Absolute neutrophil count  10
9 cells
per l (median and range)
2.4 (0.5–10.5) 2.5 (0.5–10.5) 2.1(1.7–7.0) 3.2 (1.9–4.1) 0.54
Absolute lymphocyte count  10
9 cells
per l (median and range)
1.4 (0.25–18.5) 1.3 (0.25–18.5) 1.6 (1.2–2.1) 1.4 (0.6–2.3) 0.67
Platelet count  10
9 cells per l
(median and range)
235 (47–1800) 230(52–780) 221 (47–1800) 312 (70–330) 0.89
Serum ferritin at diagnosis mgl
 1
(median and range)
330 (8–3599) 320 (8–3599) 540 (340–1432) 330 (300–660) 0.09
Transfusion need at diagnosis (%) 61 (69) 52 (67) 5 (100) 4 (80) 0.12
Disease transformation (n, %) AML (5,6) AML (5,6) 0 0 0.50
CMML (1,1) CMML (1,1)
RAEB-2 (1,1) RAEB-2 (1,1)
Number of deaths (%) 60 (68) 50 (64) 5 (100) 5 (100) 0.60
Follow-up duration in months
(median and range)
33 (0–158) 31 (0–158) 35 (4–96) 44.2 (0.4–102) 0.61
Abbreviations: AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; F, female; JAK2, janus kinase 2; M, male; MCV, mean
corpuscular volume; RAEB-2, refractory anemia with excess blasts-2.
aP-values are for comparison of JAK2V617F-positive and -negative groups.
Table 1 Spectrum of hematological disorders associated with isolated del(5q) and information on their JAK2V617F mutational status and
subsequent disease transformation
Diagnosis JAK2V617F negative
(n¼142)
JAK2V617F
positive (n¼16)
JAK2V617F
unknown (n¼32)
Total (n¼190)
(%)
Subsequent disease
transformation (n)
WHO-deﬁned ‘MDS
with isolated del(5q)’
78 5 5 88 (46) AML (5)
RAEB-1 (1)
CMML (1)
RAEB-1 10 1 2 13 (7) AML (1)
RAEB-2 11 1 3 15 (8) AML (4)
MDS-U 0 0 2 2 (1)
CMML 2 0 2 4 (2)
RARS-T 0 1 0 1 (0.5)
MDS/MPN overlap 1 0 1 2 (1)
PV 0 5 2 7 (4) Post-PV MF (3)
ET 0 1 1 2 (1)
PMF 2 1 2 5 (3) AML (1)
MPN-U 2 1 1 4 (2)
Systemic mastocytosis 1 0 0 1 (0.5)
AML 16 0 6 22 (11) NA
Others
a 18 0 5 23 (12)
Abbreviations: AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; ET, essential thrombocytosis; JAK2, janus kinase 2; MDS,
myelodysplastic syndrome; MDS-U, MDS unclassiﬁable; MPN, myeloproliferative neoplasm; MPN-U, MPN unclassiﬁable; NA, not applicable;
PMF, primary myeloﬁbrosis; PV, polycythemia vera; RAEB, refractory anemia with excess blasts; RARS-T, refractory anemia with ringed sideroblasts
with thrombocytosis; WHO, world health organization.
aOthers include patients with plasma cell dyscrasias and lymphoproliferative disorders that were noted to have an isolated del 5(q) on cytogenetics,
with no overt features of myelodysplasia based on bone marrow morphology.
MDS with isolated del(5q)
MM Patnaik et al
1285
Leukemiaand leukemic transformation was 30 months (range, 8–39).
None of the cases with disease transformation carried JAK2 or
MPL mutations. Four of the ﬁve patients with leukemic
transformation had additional cytogenetic abnormalities at the
time of transformation, including del(7q). The number of
patients with leukemic transformation was too small to allow
formal analysis of leukemia-free survival.
Overall median survival was 66 months. Table 5 outlines the
results of univariate and multivariable survival analyses regard-
ing the impact of parameters at diagnosis on survival. Age X70
years, red blood cell transfusion need and the presence of BM
dysgranulopoiesis were identiﬁed as independent predictors of
inferior survival. These three risk factors were then used to
construct low- (no risk factors), intermediate- (presence of one
risk factor) and high (presence of two or three risk factors)-risk
patient groups. The corresponding median survivals were 102,
52 and 27 months, respectively (P¼0.002; Figure 1). Of note,
there was no signiﬁcant association between survival and serum
ferritin.
Discussion
The current study is unique in several aspects. First, it is one of
few studies, possibly the only one, which strictly adhered to the
2008 WHO criteria in selecting study patients with ‘MDS with
isolated del(5q)’. This is not a trivial matter as patient selection
methods greatly affect the interpretation of clinical outcome
data and information on molecular phenotype. Second, this is
Table 4 Clinical and pathological characteristics of patients with the World Health Organization (WHO)-deﬁned ‘myelodysplastic syndrome
with isolated del(5q)’ and associated MPL mutations
Variable Patient 1 Patient 2 Patient 3
Age/sex 76/F 72/F 75/F
Molecular analysis MPLW515L MPLW515L MPLW515L
JAK2V617F
Transfusion need at presentation No No Yes
Hemoglobin (g per 100ml) 11.0 11.3 7.6
MCV (ﬂ) 104 110 102
Leukocyte count ( 10
9 cells per l) 5.5 3.2 3.8
Absolute lymphocyte count ( 10
9 cells per l) 2.6 0.9 1.2
Absolute monocyte count ( 10
9 cells per l) 0.6 0.8 1.0
Platelet count ( 10
9 cells per l) 340 326 417
Serum ferritin (mgl
 1) 340 230 3500
5q break point 5q33 5q33 5q33
BM dyserythropoiesis Yes No No
BM dysgranulopoiesis Yes No No
BM dysmegakaryopoiesis No Yes Yes
Disease transformation No No No
Survival (months) 171 25 61
Status at last follow-up Alive Alive Alive
Abbreviations: BM, bone marrow; JAK2, janus kinase 2; MCV, mean corpuscular volume; MPL, myeloproliferative leukemia virus oncogene
(thrombopoietin receptor).
Table 5 Prognostic factors for survival in 88 patients with World
Health Organization (WHO)-deﬁned ‘myelodysplastic syndrome with
isolated del(5q)’
Variable Univariate analysis
(P-value)
Multivariable analysis
(P-value)
Age 0.004
Age X70 years 0.01 0.02
Sex 0.13
Hb 0.58
MCV 0.57
WBC 0.86
ALC 0.68
AMC 0.97
Platelets 0.2
Serum ferritin 0.21
Dyserythropoiesis 0.76
Dysgranulopoiesis 0.02 0.01
Dysmegakaryopoiesis 0.57
Transfusion need at
presentation
0.04 0.04
Abbreviations: ALC, absolute lymphocyte count; AMC, absolute
monocyte count; Hb, hemoglobin; MCV, mean corpuscular volume;
WBC, white blood count.
Table 3 Pathological and cytogenetic details of 80 patients
with World Health Organization (WHO)-deﬁned ‘myelodysplastic
syndrome with isolated del(5q)’
Pathological and cytogenetic variable Number
a
Dyserythropoiesis (%) 28 (35)
Dysgranulopoiesis (%) 16 (20)
Dysmegakaryopoiesis (%) 69 (86)
Dysplasia affecting a single cell line (%) 36 (45)
Dysplasia affecting two cell lines (%) 27 (34)
Dysplasia affecting all three cell lines (%) 6 (7)
Abnormal metaphases with isolated del(5q)
(median, range)
13 (2–26)
5q breakpoints (%)
5q13q22 2 (2)
5q13q33 51(57)
5q15q31 3 (3)
5q15q33 21 (24)
5q22q31 4 (5)
5q22q33 4 (5)
5q22q35 3 (3)
aPlease note that bone marrow and peripheral smears were available
for pathological re-review in 80 patients; cytogenetic information was
available for re-review in 88 patients. Seven patients had no overt
evidence of myelodysplasia.
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patient population and its clinical value is further enhanced by
the availability of mature survival data. As a result, we were able
to conﬁrm the relatively indolent natural history of the disease
and provide critical information regarding prognostic factors,
the lack of survival impact from iron overload and baseline risk
of leukemic transformation. The overall results of the current
study are unlikely to have been affected by the 20% of the
patients who received lenalidomide therapy, considering the
fact that only 28% of them became transfusion-independent
as a result.
In 1974, Van den Berghe et al.
2 ﬁrst described the
‘5q  syndrome’. Subsequent studies have analyzed the clinical
and pathological correlates for patients with MDS and del(5q),
but often included patients with excess blasts or additional
cytogenetic abnormalities.
3–8 Most of these studies have
reiterated the obvious fact that the presence of excess blasts or
additional cytogenetic abnormalities adversely affects survival
and increases the risk of leukemic transformation.
3–8 What has
been conspicuously missing is the information on long-term
survival and prognostic factors limited to patients who ﬁt strictly
into WHO criteria for ‘MDS with isolated del(5q)’. The current
study effectively addresses this particular issue by disclosing a
more than 5-year overall median survival, which is even longer
in patients below the age of 70 years and in the absence of both
transfusion need at diagnosis and dysgranulopoiesis. We have
previously reported on the adverse impact of dysgranulopoiesis
on the survival of patients with MDS and isolated del(5q).
17
However, nearly half of the 68 patients in that particular study
did not meet the WHO criteria for ‘MDS with isolated del(5q)’,
and the study population analyzed for survival included cases
with refractory anemia with excess blast.
17
The ﬁnding that dysgranulopoiesis has potential adverse
prognostic impact in these patients is a unique observation that
warrants further study and conﬁrmation. As opposed to other
prognostic variables, dysgranulopoiesis is a factor that can be
easily determined at the time of diagnosis and needs to be
evaluated as part of any ‘MDS with isolated del(5q)’ BM
evaluation. The presence of dysgranulopoiesis could also be
a possible factor for the variably reported median survivals
in previous studies of patients with del(5q). Regardless, it is
currently not clear whether dysgranulopoiesis in ‘MDS with
isolated del(5q)’ identiﬁes patients with a different disease or
represents an acquired histological marker of clonal evolution.
17
JAK2V617F and MPLW515L are gain-of-function mutations
that are characteristically associated with MPN and are only
infrequently seen in patients with MDS.
18,19 A previous multi-
center study of 81 patients with MDS and isolated del(5q)
identiﬁed six patients with JAK2V617F, all occurring in patients
with less than 5% BM blasts. The JAK2-mutated patients in this
study displayed signiﬁcantly higher leukocyte count and a trend
toward a higher platelet count. However, it is not clear what
constituted the comparison group, as the study population
included 27 patients with excess blasts.
20 In our study, there was
no signiﬁcant difference in blood counts or clinical outcome
between patients with and without JAK2V617F. In MPN, the
presence of JAK2V617F has been associated with older age at
diagnosis, higher hemoglobin level, leukocytosis and lower
platelet count.
21 Obviously, the small sample sizes in the
del(5q)-related studies do not allow one to make statistically
valid conclusions on the phenotypic effect of mutant JAK2 in
that setting. Incidentally, a recent study looked into the clonal
structure of JAK2V617F-mutated MDS with isolated del(5q) and
showed that the del(5q) and JAK2V617F clones were mutually
exclusive.
22
The current study is the ﬁrst to show the presence of MPL
mutations in B4% of patients with ‘MDS with isolated del(5q)’
and absence of the recently described IDH1 and IDH2
mutations.
23,24 None of the MPL-mutated patients displayed
thrombocytosis. MPLW515L, MPLW515K and other exon 10
MPL mutations have been described in essential thrombocythe-
mia and primary myeloﬁbrosis with mutational frequencies that
range from 3 to 15%.
13,25–29 MPLW515L is the most frequent
MPN-associated MPL mutation. In essential thrombocythemia,
Low risk; n=19; median survival 102 months
Intermediate risk; n=52; median survival 52 months
High risk; n=10; median survival 27 months
P=0.002
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Figure 1 Kaplan–Meier survival curves for 88 patients with World Health Organization (WHO)-deﬁned ‘myelodysplastic syndrome with isolated
del(5q)’. Overall median survival was 66 months. The ﬁgure shows median survival of patients belonging to three risk categories based on the
presence of zero (low risk), one (intermediate risk) or X2 (high risk) of the following risk factors: age X70 years, transfusion need at presentation
and the presence of bone marrow dysgranulopoiesis.
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age, lower hemoglobin level, higher platelet count, micro-
vascular symptoms and a higher risk of post-diagnosis arterial
thrombosis.
29,30 In primary myeloﬁbrosis, the associated factors
were female sex, older age, lower hemoglobin level and a
higher likelihood of becoming transfusion dependent.
28 Again,
the number of MPL-mutated patients in the current study was
too small to allow making any comparative remarks.
With regard to IDH mutations, they were ﬁrst described in
gliomas
31 and subsequently in AML.
24,32,33 Mutational fre-
quency of IDH1 in primary AML is B9% and the mutations
usually cluster with normal karyotype, although a possible
association with trisomy 8 has been suggested.
24 More recently,
IDH2 mutations were also reported in primary AML.
32,33 IDH
mutations have also been described in secondary AML,
including patients with antecedent MPN or MDS.
23,34,35 In the
two most recent studies, IDH mutations were shown in more
than 20% of patients with post-MPN AML, B4% of those
with primary myeloﬁbrosis and rarely in PV or essential
thrombocythemia.
23,35 To date, there is no information on the
prevalence of IDH mutations in MDS.
In December 2005, based on encouraging results seen with
lenalidomide in the treatment of transfusion-dependent, lower-
risk patients with MDS and del(5q), the United States Food and
Drug Administration (FDA) approved lenalidomide therapy for
this indication.
6,36 Patients who received lenalidomide achieved
a red cell transfusion independence rate of 67% and a complete
cytogenetic response rate of 45%.
6 More recently, concerns
have been voiced regarding drug-induced leukemogenicity,
especially in those patients who do not respond to treatment.
37
In one long-term study with a median follow-up of 40 months,
15 (36%) of 42 lenalidomide-treated patients with low- or
intermediate-risk MDS and del(5q) had transformed to AML.
37
This ﬁgure is much higher than expected in a patient population
that ﬁts the WHO criteria for ‘MDS with isolated del(5q)’.
However, a substantial number of the lenalidomide-treated
patients in the particular study displayed excess blasts at study
entry and are therefore not comparable with the patient
population in the current study. It is also interesting to surmise
that the presence of dysgranulopoiesis could also be a
contributing factor to disease progression in these lenalido-
mide-treated patients. A carefully designed randomized study is
needed to resolve such issues. In the mean time, it would be
interesting to query currently existing databases of lenalido-
mide-treated patients with MDS and estimate the risk of
leukemic transformation in those patients who meet the WHO
criteria for ‘MDS with isolated del(5q)’, and compare them with
the baseline risk established from the current study.
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